A perspective on integrating digital pathology, proteomics, clinical data and AI analytics in cancer research
Nearly 40 % of individuals will be diagnosed with cancer in their lifetime, translating to an estimated 20 million new cases annually. Despite remarkable therapeutic advances, only 15–20 % of patients achieve durable responses to immunotherapy, and the high cost of treatment (illustrated by immune checkpoint inhibitors like pembrolizumab and nivolumab, totaling roughly $191,000 per year) remains a
